Home/Disease Specific/Osteoporosis

Clinical Trial Targeting Lung Cancer, Plus Promising Osteoporosis and Incontinence Research get Support from Stem Cell Agency

The five-year survival rate for people diagnosed with the most advanced stage of non-small cell lung cancer (NSCLC) is between one and 10 percent. To address this devastating condition, the Board of the California Institute for Regenerative Medicine (CIRM) today voted to invest almost $12 million in a team from UCLA that is pioneering a

Supplements Do Not Prevent Fractures in Healthy Older Adults

A meta-analysis of multiple randomized trials does not support the use of either calcium or vitamin D supplements or their combination to reduce fracture risk of any kind in healthy older adults, Chinese investigators reaffirm. "The increased social and economic burdens for osteoporosis-related fractures worldwide make the prevention of such injuries a major public health

January 8th, 2018|Categories: Disease Specific, Osteoporosis|Tags: , , , |

Biomarker Predicts Fracture Risk in Older Women

Circulating levels of a protein biomarker predicts the risk of postmenopausal women having a low-trauma fracture independent of their areal bone-mineral density (aBMD) status, classical bone-turnover markers (BTMs) and Fracture Risk Assessment Tool (FRAX) score, new research shows. The study was published online August 2 in the Journal of Bone and Mineral Research. Nicolas Bonnet,

September 10th, 2017|Categories: Disease Specific, Osteoporosis|Tags: , , |

Bare bones: Making bones transparent

April 26, 2017 (Nanowerk News) Ten years ago, the bones currently in your body did not actually exist. Like skin, bone is constantly renewing itself, shedding old tissue and growing it anew from stem cells in the bone marrow. Now, a new technique developed at Caltech can render intact bones transparent, allowing researchers to observe

UC Davis licenses novel compound that helps stem cells regenerate bone to treat bone diseases

March 3, 2017 Hybrid molecule LLP2A-Alendronate could have implications for osteonecrosis, fractures, osteoporosis and inflammatory arthritis. The University of California, Davis, is pleased to announce a licensing agreement with Regenerative Arthritis and Bone Medicine, Inc. (RABOME) for a class of drugs developed at UC Davis that hold potential for treating diseases associated with bone loss